Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.64 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.50 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.50 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL17203250 | 0.98 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| Sulfuric Acid SCHEMBL17203127 | 0.97 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| Sulfuric Acid SCHEMBL17203266 | 0.97 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| Sulfuric Acid SCHEMBL17202951 | 0.97 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| Sulfuric Acid SCHEMBL17202949 | 0.97 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| Phosphoric Acid SCHEMBL17203108 | 0.95 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48826 | 0.90 | PIK3CD (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48709 | 0.90 | PIK3CD (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL49251 | 0.89 | PIK3CD (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48872 | 0.87 | PIK3CD (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| WO-2015162584-A1 | CRYSTALLINE FORMS OF THE SULFATE SALT OF N-[5-(3-IMIDAZOL-1-YL-4-METHANESULFONYL-PHENYL)-4-METHYL-THIAZOL-2-YL]-ACETAMIDE | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162584-A1 | CRYSTALLINE FORMS OF THE SULFATE SALT OF N-[5-(3-IMIDAZOL-1-YL-4-METHANESULFONYL-PHENYL)-4-METHYL-THIAZOL-2-YL]-ACETAMIDE | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162584-A1 | CRYSTALLINE FORMS OF THE SULFATE SALT OF N-[5-(3-IMIDAZOL-1-YL-4-METHANESULFONYL-PHENYL)-4-METHYL-THIAZOL-2-YL]-ACETAMIDE | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| EP-1689391-B1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CG 8/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | PIK3CG 6/4885PIK3CD 12/4885PIK3CA 1/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | PIK3CG 6/4885PIK3CD 10/4885PIK3CA 1/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | PIK3CG 23/4885PIK3CD 26/4885PIK3CA 16/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CG 8/4885PIK3CD 4/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.